Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
21 September 2026
Are you cyber ready? Australian legal leaders' views on the cyber risk landscape
21 September 2026
Cross Examining Cyber: Conversations with cyber leaders
1 September 2026
The Unified patent court and unitary patent – An introduction
11 August 2026
The new cost of capital for early investment in Indonesia: Governance, diligence and recalibration
11 August 2026
Indonesian Hospitals: Key Regulatory Changes to Hospital Classification, Investment and Operations
30 July 2026
Three years of the UPC – A court coming of age
20 April 2026
FDA pushes for broader powers to curb misleading direct to consumer drug advertising
1 April 2026
UPC Structure – local, regional and central divisions and Court of Appeal, Judges & Languages
19 March 2026
Pharmaceuticals: Deals revival
19 March 2026
Snapshot: Key European pharma regulatory, IP and competition developments from 2025 for the pharmaceutical sector
12 March 2026
Pharma: Key UK legal developments from 2025
12 February 2026
Corporate Crime 360: Your complete guide to APAC trends in 2026
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane